IBRI Technology Update: Diseases Diagnosed Faster and Better
Illustration of antibodies binding to bacteria.
In 2020, the IBRI outlicensed one of the technologies developed by IBRI researchers to BioMEMS Analytics, LLC, a startup company based in Indiana. The technology licensed is a biological electromechanical system that uses micro-sized components to reduce cost and improve sensitivity of diagnostic tests.
This technology shows our focus on the future of translational science in a patient-centric framework. Indeed, at the heart of this technology is an innovative approach to diagnose diseases faster and with more precision, allowing a quicker translation from patient diagnosis to effective treatment.